Phase 2, multicenter, randomized, double-blind (within dose level), placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of TF0023 versus placebo in the treatment of COVID-19. XNUMX in hospitalized adults.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: TECHFIELDS INC
- Phase: II
- Execution start: 10/08/2022
- End of execution: 30/01/2024
- PI: JUAN PASQUAU LIAÑO